Read the latest news about research on treatments for Alzheimer's disease.
The last drug approved by the FDA was in 2003, and until now any treatment has proved to slow down the progression of the disease.
Dr José Luis Molinuevo comments the possible approval of Biogen’s new treatment, in an interview for the podcast Saving Minds.
The aim of the conferences is to bring scientific research closer to people
The scientific director of BBRC's Alzheimer’s Prevention Program suggests trying a new aproach in order to keep working with Aducanumab
The aim of the project, entitled AlfaAge, is to identify pro-ageing and pro-youthful blood biomarkers in different age groups.
The project has received funding from the European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie action grant agreement No 752310.
CTAD conference took place in Barcelona, from the 24th to the 27th of October.
The studies will analyze the efficacy of various pharmacological treatments designed to act before the manifestation of the clinical symptoms of the disease.